Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.

IF 3.1 2区医学 Q2 CLINICAL NEUROLOGY

Journal of Neuro-Oncology Pub Date : 2025-10-16 DOI:10.1007/s11060-025-05250-3

Vincent Harlay, Céline Bequet, Romain Appay, Alexandre Bertucci, Gregorio Petrirena, Chantal Campello, Maryline Barrié, Didier Autran, Thomas Graillon, Henry Dufour, Dominique Figarella-Branger, Laetitia Padovani, Anne Barlier, Isabelle Nanni, Emeline Tabouret, Olivier Chinot

{"title":"Autonomy duration in patients with biopsy-only unresectable IDH wild-type glioblastomas.","authors":"Vincent Harlay, Céline Bequet, Romain Appay, Alexandre Bertucci, Gregorio Petrirena, Chantal Campello, Maryline Barrié, Didier Autran, Thomas Graillon, Henry Dufour, Dominique Figarella-Branger, Laetitia Padovani, Anne Barlier, Isabelle Nanni, Emeline Tabouret, Olivier Chinot","doi":"10.1007/s11060-025-05250-3","DOIUrl":null,"url":null,"abstract":"Purpose: \"Biopsy-only\" glioblastoma (BO-GB) is an understudied entity associated with a poor outcome for whom quality of life preservation is essential. Our objective was to define and determine the time of autonomy duration in BO-GB and its potential predictive factors.Methods: Patients diagnosed with IDH wild-type BO-GB and enrolled in a prospective regional cohort from 2014 to 2017 were analyzed for their clinical features, functional status, histo-molecular profile, neuroimaging findings, and treatment details.Results: 137 patients were included in the present analysis. Median age at inclusion was 66 years old and median KPS was 70. Median time of autonomy duration was 7.7 months (CI95%: 5.6-9.7). In the radiotherapy - temozolomide subgroup, median time of autonomy duration was 9.1 months (CI95%: 8.1-10.3); in the chemotherapy upfront group, median time of autonomy duration was 5.3 months (CI95%: 3.5-7.1). Autonomy duration was correlated to patient age and overall survival but not with initial functional status. Among the 65 patients with KPS < 70 at baseline, 11 patients (16.9%) restored their autonomy under treatment. Autonomy duration was not different between these 11 patients and the patients with baseline KPS ≥ 70 (p = 0.758).Conclusion: Autonomy duration may serve as a surrogate endpoint for overall survival for BO-GB patients and may be included in future clinical trials dedicated to this frail population.","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":"176 1","pages":"20"},"PeriodicalIF":3.1000,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-025-05250-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: "Biopsy-only" glioblastoma (BO-GB) is an understudied entity associated with a poor outcome for whom quality of life preservation is essential. Our objective was to define and determine the time of autonomy duration in BO-GB and its potential predictive factors.

Methods: Patients diagnosed with IDH wild-type BO-GB and enrolled in a prospective regional cohort from 2014 to 2017 were analyzed for their clinical features, functional status, histo-molecular profile, neuroimaging findings, and treatment details.

Results: 137 patients were included in the present analysis. Median age at inclusion was 66 years old and median KPS was 70. Median time of autonomy duration was 7.7 months (CI95%: 5.6-9.7). In the radiotherapy - temozolomide subgroup, median time of autonomy duration was 9.1 months (CI95%: 8.1-10.3); in the chemotherapy upfront group, median time of autonomy duration was 5.3 months (CI95%: 3.5-7.1). Autonomy duration was correlated to patient age and overall survival but not with initial functional status. Among the 65 patients with KPS < 70 at baseline, 11 patients (16.9%) restored their autonomy under treatment. Autonomy duration was not different between these 11 patients and the patients with baseline KPS ≥ 70 (p = 0.758).

Conclusion: Autonomy duration may serve as a surrogate endpoint for overall survival for BO-GB patients and may be included in future clinical trials dedicated to this frail population.

查看原文本刊更多论文

仅活检不能切除的IDH野生型胶质母细胞瘤患者的自主持续时间。

目的：“仅活组织检查”胶质母细胞瘤（BO-GB）是一种未被充分研究的实体，与预后不良相关，对其生活质量保存至关重要。我们的目的是定义和确定BO-GB的自主持续时间及其潜在的预测因素。方法：对2014 - 2017年诊断为IDH野生型BO-GB的前瞻性区域队列患者的临床特征、功能状态、组织分子谱、神经影像学表现和治疗细节进行分析。结果：137例患者纳入本分析。入组时的中位年龄为66岁，中位KPS为70岁。自主持续时间中位数为7.7个月（CI95%: 5.6-9.7）。放疗-替莫唑胺亚组中位自主持续时间为9.1个月（CI95%: 8.1-10.3）；化疗前期组自主持续时间中位数为5.3个月（CI95%: 3.5 ~ 7.1）。自主性持续时间与患者年龄和总生存期相关，但与初始功能状态无关。结论：自主持续时间可作为BO-GB患者总生存期的替代终点，并可纳入未来针对这一虚弱人群的临床试验。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Neuro-Oncology 医学-临床神经学

CiteScore

6.60

自引率

7.70%

发文量

277

审稿时长

3.3 months

期刊介绍： The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.